New research: GLP-1 drugs are safe and effective in obese children without diabetes
Points clés
- GLP-1 drugs have been found to be safe and effective in obese children without diabetes.
- The research was presented at the congress organized by the World Obesity Federation in Mexico between July 15-17.
- The study was prepared by Dr. Manpreet Kaur Oberoi and her team from the University of Western Ontario in Canada.
En chiffres
New research presented at the International Congress on Obesity (ICO2026) held in Mexico reveals that GLP-1 receptor agonists can be used for weight loss in obese children who do not have diabetes. The study is considered a promising step in the treatment of pediatric obesity, documenting that this group is both safe and effective.
The team conducting the research, led by Dr. Manpreet Kaur Oberoi from the University of Western Ontario, performed a comprehensive data analysis covering children in different age groups. The findings indicate that these Ozempic-like drugs can be an appropriate treatment option not only in adults but also at early ages.
Réagir à cet article
Poser une question
Réponses générées par IA, à partir de cette actualité uniquement.
Questions fréquentes
- Q: Are GLP-1 drugs suitable for children according to this new research?
- A: Yes, according to the research, the use of GLP-1 drugs in obese children without diabetes has been found to be safe and effective.
- Q: At which event was the research presented?
- A: The study was presented to scientists at the International Congress on Obesity (ICO2026) held in Mexico.
- Q: Which institution and scientist conducted the research?
- A: The research was conducted and the results were shared by Dr. Manpreet Kaur Oberoi and her colleagues from the University of Western Ontario.
Ceci est un court résumé généré par l'IA. L'article complet est à la source.
Lire l'article complet à la sourcemedicalxpress.comComment nous produisons notre contenu →